Screener
Eton Pharmaceuticals, Inc. ETON Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Interest and other expense, net | (840) | (1,028) |
| Income (loss) before income tax expense | 1,574 | (1,498) |
| Income tax expense | 20 | 74 |
| Net income (loss) | $1,554 | $(1,572) |
| Net income (loss) per share, basic | $0.06 | $(0.06) |
| Weighted average number of common shares outstanding, basic | 27,285 | 26,886 |
| Net income (loss) per share, diluted | $0.05 | $(0.06) |
| Weighted average number of common shares outstanding, diluted | 31,547 | 26,886 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s net income?
- Eton Pharmaceuticals, Inc. (ETON) reported net income of $1.55M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s net income changed year-over-year?
- Eton Pharmaceuticals, Inc.'s net income increased by 198.9% year-over-year, from -$1.57M to $1.55M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Eton Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude